Lung cancer screening in Kazakhstan: who can undergo it and where

Lung cancer screening in Kazakhstan: who can undergo it and where

Tengrinews.kz — Prime Minister Olzhas Bektenov has announced plans to launch a pilot lung cancer screening program in Kazakhstan using low-dose computed tomography. The information was included in his response to a parliamentary inquiry.

Where screening will begin

The pilot project is planned for four regions with the highest incidence rates: East Kazakhstan, Karaganda and Zhambyl regions, as well as Ulytau Region.

According to Bektenov, preparations for the program are already underway.

“Training activities for healthcare workers have already been conducted,” the response said.

Low-dose computed tomography (CT) has been selected as the screening method.

Note: Low-dose computed tomography (LDCT) of the lungs is a type of CT scan that uses a significantly lower dose of X-ray radiation than a standard diagnostic CT scan. It provides detailed cross-sectional images of the lungs and can detect small abnormalities, including nodules that may be an early sign of cancer.

Specialists have identified a group of people at higher risk of developing lung cancer. They will be eligible for screening.

The program will include men and women aged 50 to 70 who currently smoke or quit less than 15 years ago.

Smoking history will also be taken into account using the “pack-year” measure. Kazakhstan’s program sets the threshold at 20 pack-years — in other words, a person who smokes one pack of cigarettes a day for 20 years would fall into the target screening group.

Why the domestic AI system was not introduced

Earlier, Kurultai deputy Sergei Ponomaryov asked Prime Minister Olzhas Bektenov to look into the reasons for the delay in introducing a domestically developed artificial intelligence system for the early detection of lung cancer.

According to the deputy, the system was developed in 2023 with a World Bank grant and technically integrated with 200 medical organizations across the country.

In response to the inquiry, Bektenov said that in 2024 the Health Ministry’s Joint Commission on the Quality of Medical Services reviewed the system but postponed its introduction due to insufficient evidence of effectiveness.

According to the Prime Minister, over two years the developer failed to provide clinical trial data or publications in scientific journals confirming the system’s effectiveness. The technology cannot be used in medical practice without a positive conclusion from the commission.

As a reminder, around 70 percent of lung cancer cases in Kazakhstan are detected only at stages three or four, when treatment is less effective. Lung cancer remains one of the most common cancers in Kazakhstan and one of the leading causes of death from malignant tumors.